Merck Tbk (MERK) - Total Liabilities
Based on the latest financial reports, Merck Tbk (MERK) has total liabilities worth Rp154.71 Billion IDR (≈ $9.07 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Merck Tbk to track the company's year-over-year net asset growth rate.
Merck Tbk - Total Liabilities Trend (2000–2024)
This chart illustrates how Merck Tbk's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Merck Tbk to measure how efficiently the company converts operating cash flow to free cash.
Merck Tbk Competitors by Total Liabilities
The table below lists competitors of Merck Tbk ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Black Diamond Therapeutics Inc
NASDAQ:BDTX
|
USA | $28.62 Million |
|
Entre Cua Socimi
MC:YENT
|
Spain | €34.65 Million |
|
Papoutsanis S.A
AT:PAP
|
Greece | €47.64 Million |
|
Amica S.A.
WAR:AMC
|
Poland | zł930.90 Million |
|
Loxley Public Company Limited
BK:LOXLEY
|
Thailand | ฿6.19 Billion |
|
Marks and Spencer Group PLC
LSE:MKS
|
UK | GBX6.89 Billion |
|
KB Star REIT Co. Ltd.
KO:432320
|
Korea | ₩935.70 Billion |
|
Kreate Group Oyj
HE:KREATE
|
Finland | €95.50 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Merck Tbk's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Merck Tbk stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Merck Tbk's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Merck Tbk (2000–2024)
The table below shows the annual total liabilities of Merck Tbk from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Rp149.66 Billion ≈ $8.77 Million |
-7.58% |
| 2023-12-31 | Rp161.94 Billion ≈ $9.49 Million |
-42.25% |
| 2022-12-31 | Rp280.41 Billion ≈ $16.43 Million |
-18.06% |
| 2021-12-31 | Rp342.22 Billion ≈ $20.05 Million |
+7.88% |
| 2020-12-31 | Rp317.22 Billion ≈ $18.59 Million |
+3.31% |
| 2019-12-31 | Rp307.05 Billion ≈ $17.99 Million |
-58.78% |
| 2018-12-31 | Rp744.83 Billion ≈ $43.64 Million |
+221.65% |
| 2017-12-31 | Rp231.57 Billion ≈ $13.57 Million |
+43.60% |
| 2016-12-31 | Rp161.26 Billion ≈ $9.45 Million |
-4.07% |
| 2015-12-31 | Rp168.10 Billion ≈ $9.85 Million |
+3.19% |
| 2014-12-31 | Rp162.91 Billion ≈ $9.55 Million |
-11.81% |
| 2013-12-31 | Rp184.73 Billion ≈ $10.82 Million |
+20.98% |
| 2012-12-31 | Rp152.69 Billion ≈ $8.95 Million |
+69.27% |
| 2011-12-31 | Rp90.21 Billion ≈ $5.29 Million |
+25.72% |
| 2010-12-31 | Rp71.75 Billion ≈ $4.20 Million |
-10.07% |
| 2009-12-31 | Rp79.79 Billion ≈ $4.68 Million |
+67.13% |
| 2008-12-31 | Rp47.74 Billion ≈ $2.80 Million |
-6.08% |
| 2007-12-31 | Rp50.83 Billion ≈ $2.98 Million |
+7.87% |
| 2006-12-31 | Rp47.12 Billion ≈ $2.76 Million |
+25.13% |
| 2005-12-31 | Rp37.66 Billion ≈ $2.21 Million |
-18.89% |
| 2004-12-31 | Rp46.43 Billion ≈ $2.72 Million |
+13.75% |
| 2003-12-31 | Rp40.82 Billion ≈ $2.39 Million |
+76.78% |
| 2002-12-31 | Rp23.09 Billion ≈ $1.35 Million |
-34.45% |
| 2001-12-31 | Rp35.23 Billion ≈ $2.06 Million |
+7.30% |
| 2000-12-31 | Rp32.83 Billion ≈ $1.92 Million |
-- |
About Merck Tbk
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through Biopharma, Consumer Health, and Others segments. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in research an… Read more